Skip to content

Study · Not a test of the peptide alone · 2014

3 results

Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.

Thevis M, Thomas A, Geyer H, Schänzer W

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Dec 2014Cited by 8 (Europe PMC)

PMID25466910 (opens in a new tab)DOI10.1016/j.ghir.2014.10.004 (opens in a new tab)PepBankPUB-25466910
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MGF / PEG-MGF.

  1. 01LabNot a test of MGF / PEG-MGF aloneIn vitro (cell-free)Other

    Mass spectrometry identified a protein of 12264.9 Da with a sequence closely related to IGF-1Ec in a product sold as full-length MGF.

    In plain wordsIn lab tests, a product sold as full-length MGF was a protein of 12264.9 Da, closely related to IGF-1Ec.

    Peptide
    MGF / PEG-MGF
    Outcome
    Not applicableMolecular mass and sequence of full-length MGF product
    Study

    n: not reported in source

    full-length MGF product obtained from illicit channels
    Outcome group
    Product quality and purity · Pharmacology

    Measurements

    Monoisotopic molecular mass
    12264.9 Da
    full-length MGF product

    Source sentences

    Summary
    A protein with a monoisotopic molecular mass of 12264.9 Da and a sequence closely related to IGF-1Ec (lacking the signal- and propeptide moiety) was identified.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  2. 02LabNot a test of MGF / PEG-MGF aloneIn vitro (cell-free)Other

    The C-terminus of the full-length MGF product lacked the terminal lysine and carried an R109H substitution.

    In plain wordsIn lab tests, the product's end was missing a lysine and carried one amino acid change.

    Peptide
    MGF / PEG-MGF
    Outcome
    Not applicableC-terminal modification and R109H substitution
    Study

    n: not reported in source

    full-length MGF product obtained from illicit channels
    Outcome group
    Product quality and purity · Pharmacology

    Source sentences

    Summary
    The C-terminus was found to be modified by the elimination of the terminal lysine and a R109H substitution.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  3. 03LabNot a test of MGF / PEG-MGF aloneIn vitro (cell-free)Other

    Adapted routine doping-control methods using immunoaffinity purification and nanoLC-HRMS detected the analyte at 0.25 ng/mL.

    In plain wordsIn lab tests, an adapted doping-control method detected the product at 0.25 ng/mL.

    Peptide
    MGF / PEG-MGF
    Outcome
    Not applicableDetection limit in doping control method
    Study

    n: not reported in source

    full-length MGF product obtained from illicit channels
    Outcome group
    Product quality and purity · Pharmacology

    Measurements

    Detectable concentration
    0.25 ng/mL
    immunoaffinity purification with nanoLC-HRMS

    Source sentences

    Summary
    The analyte was detectable at concentrations of 0.25 ng/mL using adapted routine test methods employing immunoaffinity purification followed by nanoscale liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.